![Sequential high-dose cytarabine and mitoxantrone (S-HAM) versus standard double induction in acute myeloid leukemia—a phase 3 study | Leukemia Sequential high-dose cytarabine and mitoxantrone (S-HAM) versus standard double induction in acute myeloid leukemia—a phase 3 study | Leukemia](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41375-018-0268-9/MediaObjects/41375_2018_268_Fig1_HTML.png)
Sequential high-dose cytarabine and mitoxantrone (S-HAM) versus standard double induction in acute myeloid leukemia—a phase 3 study | Leukemia
![Mitigating acute chemotherapy-associated adverse events in patients with cancer | Nature Reviews Clinical Oncology Mitigating acute chemotherapy-associated adverse events in patients with cancer | Nature Reviews Clinical Oncology](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41571-022-00685-3/MediaObjects/41571_2022_685_Fig1_HTML.png)
Mitigating acute chemotherapy-associated adverse events in patients with cancer | Nature Reviews Clinical Oncology
![The prevalence of the less common side-effects observed in the two groups | Download Scientific Diagram The prevalence of the less common side-effects observed in the two groups | Download Scientific Diagram](https://www.researchgate.net/publication/355919650/figure/tbl2/AS:1086623466958852@1636082631845/The-prevalence-of-the-less-common-side-effects-observed-in-the-two-groups.png)
The prevalence of the less common side-effects observed in the two groups | Download Scientific Diagram
![When chemotherapy interrupts genetic programs critical for neuronal development and activity, cells accrue DNA damage and die | Center for Cancer Research When chemotherapy interrupts genetic programs critical for neuronal development and activity, cells accrue DNA damage and die | Center for Cancer Research](https://ccr.cancer.gov/sites/default/files/2022-12/Nussenzweig_Nov2022.jpg)
When chemotherapy interrupts genetic programs critical for neuronal development and activity, cells accrue DNA damage and die | Center for Cancer Research
![Targeting SAMHD1 with hydroxyurea in first‐line cytarabine‐based therapy of newly diagnosed acute myeloid leukaemia: Results from the HEAT‐AML trial - Jädersten - 2022 - Journal of Internal Medicine - Wiley Online Library Targeting SAMHD1 with hydroxyurea in first‐line cytarabine‐based therapy of newly diagnosed acute myeloid leukaemia: Results from the HEAT‐AML trial - Jädersten - 2022 - Journal of Internal Medicine - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/3865e364-f642-4c4c-b7f0-832d633f64f5/joim13553-gra-0001-m.jpg)
Targeting SAMHD1 with hydroxyurea in first‐line cytarabine‐based therapy of newly diagnosed acute myeloid leukaemia: Results from the HEAT‐AML trial - Jädersten - 2022 - Journal of Internal Medicine - Wiley Online Library
![Induction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin: a randomized phase II trial in elderly patients - ScienceDirect Induction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin: a randomized phase II trial in elderly patients - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0923753419346460-gr1.jpg)
Induction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin: a randomized phase II trial in elderly patients - ScienceDirect
![Expression of TFRC helps to improve the antineoplastic effect of Ara-C on AML cells through a targeted delivery carrier | Journal of Nanobiotechnology | Full Text Expression of TFRC helps to improve the antineoplastic effect of Ara-C on AML cells through a targeted delivery carrier | Journal of Nanobiotechnology | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12951-023-01881-8/MediaObjects/12951_2023_1881_Fig3_HTML.png)
Expression of TFRC helps to improve the antineoplastic effect of Ara-C on AML cells through a targeted delivery carrier | Journal of Nanobiotechnology | Full Text
![Chemomodulation of sequential high-dose cytarabine by fludarabine in relapsed or refractory acute myeloid leukemia: a randomized trial of the AMLCG | Leukemia Chemomodulation of sequential high-dose cytarabine by fludarabine in relapsed or refractory acute myeloid leukemia: a randomized trial of the AMLCG | Leukemia](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fleu.2013.297/MediaObjects/41375_2014_Article_BFleu2013297_Fig1_HTML.jpg)
Chemomodulation of sequential high-dose cytarabine by fludarabine in relapsed or refractory acute myeloid leukemia: a randomized trial of the AMLCG | Leukemia
![Expression of TFRC helps to improve the antineoplastic effect of Ara-C on AML cells through a targeted delivery carrier | Journal of Nanobiotechnology | Full Text Expression of TFRC helps to improve the antineoplastic effect of Ara-C on AML cells through a targeted delivery carrier | Journal of Nanobiotechnology | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12951-023-01881-8/MediaObjects/12951_2023_1881_Sch1_HTML.png)